Business Insights, PHARMACY MARKET

Expediting early-phasedevelopment ofsmall molecules: Anintegrated approach

November 18, 2022

Expediting early
Small molecule drug development has changed substantially
in recent years. With the heightened focus on molecularly
targeted therapies, small molecule active pharmaceutical
ingredients (APIs).

Spotlight

Ardelyx, Inc.

Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States.

OTHER WHITEPAPERS
news image

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More
news image

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

U.S. Pharmaceutical Market Trend Report

whitePaper | February 28, 2022

Starting in Week 9 of 2020, prescription volume and claims data entered a period of intense volatility, followed by a steady state

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

Read More

Spotlight

Ardelyx, Inc.

Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States.

Events